Free Newsletter
Bavarian Nordic soars on FDA vax OK
Shares of Bavarian Nordic jumped more than 20 percent this morning after the company reported that the FDA had raised a green flag for the production and delivery of its smallpox vaccine Imvamune. Analysts cheered the move as a major event for the biopharma company. "This represents a transformational step in the company lifecycle of Bavarian Nordic from being a developmental, R&D focused company to an order producing pharmaceutical business," S&P says in a note. Bavarian release | Report
More stories about smallpox Bavarian Nordic
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
More Research Reports >>
SHARE
WITH: